Search research articles
Contact Us
Filters
Showing results (41-50 of 65) with videos related to
Page
of 7
Sort By:
ACR Open Rheumatology
|
February 2, 2026
Macrophage Activation Syndrome-Associated Proteins and Enhanced Interferon-γ Responsiveness in the Plasma Proteome of Patients With Multisystem Inflammatory Syndrome in Children in a Pretreatment Replication Single-Center Cohort
Sarah McCuaig, Cara Toland, Katharine C Konvinse, et al.
Clinical and Experimental Dermatology
|
December 16, 2024
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, et al.
Genetics
|
March 29, 2019
CRISPR Gene Drive Efficiency and Resistance Rate Is Highly Heritable with No Common Genetic Loci of Large Effect
Jackson Champer, Zhaoxin Wen, Anisha Luthra, et al.
JAMA Dermatology
|
March 9, 2016
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials
April W Armstrong, Charles W Lynde, Sandy R McBride, et al.
EMBO Reports
|
February 27, 2023
Climate change and public health: The effects of global warming on the risk of allergies and autoimmune diseases: The effects of global warming on the risk of allergies and autoimmune diseases
Alexandra S Lee, Juan Aguilera, Jo Ann Efobi, et al.
Advances in Therapy
|
December 5, 2024
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
Advances in Therapy
|
September 9, 2024
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
Journal of Adolescent and Young Adult Oncology
|
May 31, 2022
A Multicomponent Telehealth Intervention to Improve Oncofertility Care Delivery Among Young Cancer Patients: A Pilot Study
Emily Yang, Anna Dornisch, Laura Nerb, et al.
The British Journal of Dermatology
|
February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Brett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Clinical and Experimental Dermatology
|
November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 65) with videos related to
Sort By:
Page
of 7
ACR Open Rheumatology
|
February 2, 2026
Macrophage Activation Syndrome-Associated Proteins and Enhanced Interferon-γ Responsiveness in the Plasma Proteome of Patients With Multisystem Inflammatory Syndrome in Children in a Pretreatment Replication Single-Center Cohort
Sarah McCuaig, Cara Toland, Katharine C Konvinse, et al.
Clinical and Experimental Dermatology
|
December 16, 2024
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, et al.
Genetics
|
March 29, 2019
CRISPR Gene Drive Efficiency and Resistance Rate Is Highly Heritable with No Common Genetic Loci of Large Effect
Jackson Champer, Zhaoxin Wen, Anisha Luthra, et al.
JAMA Dermatology
|
March 9, 2016
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials
April W Armstrong, Charles W Lynde, Sandy R McBride, et al.
EMBO Reports
|
February 27, 2023
Climate change and public health: The effects of global warming on the risk of allergies and autoimmune diseases: The effects of global warming on the risk of allergies and autoimmune diseases
Alexandra S Lee, Juan Aguilera, Jo Ann Efobi, et al.
Advances in Therapy
|
December 5, 2024
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
Advances in Therapy
|
September 9, 2024
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
Journal of Adolescent and Young Adult Oncology
|
May 31, 2022
A Multicomponent Telehealth Intervention to Improve Oncofertility Care Delivery Among Young Cancer Patients: A Pilot Study
Emily Yang, Anna Dornisch, Laura Nerb, et al.
The British Journal of Dermatology
|
February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Brett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Clinical and Experimental Dermatology
|
November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
Page
of 7